Malfetano J H, Blessing J A, Jacobs A J
Department of Obstetrics and Gynecology, Albany Medical Center Hospital, New York.
Am J Clin Oncol. 1993 Feb;16(1):47-9. doi: 10.1097/00000421-199302000-00012.
Sixteen evaluable patients with advanced or recurrent epithelial ovarian carcinoma following progression on combination chemotherapy were treated with 4.2 mg/m2 of Didemnin B (NSC #325319) intravenously every 28 days until progression of disease. All patients had prior cisplatin-containing chemotherapy. There were no responders. Seven patients had stable disease (43.7%) and nine (53.3%) had increasing disease. The toxicities were significant, consisting of nausea and vomiting in seven patients (44%), one grade 3 hepatic toxicity, and three instances of grade 4 toxicities (1 leukopenia, 1 GI, and 1 GU). When used with this schedule Didemnin B is ineffective in patients with previously treated epithelial ovarian cancer.
16例晚期或复发性上皮性卵巢癌患者在联合化疗进展后接受治疗，每28天静脉注射4.2mg/m²的Didemnin B（NSC #325319），直至疾病进展。所有患者既往均接受含顺铂的化疗。无缓解者。7例患者病情稳定（43.7%），9例（53.3%）病情进展。毒性反应显著，7例患者（44%）出现恶心和呕吐，1例3级肝毒性，3例4级毒性反应（1例白细胞减少、1例胃肠道毒性和1例泌尿生殖系统毒性）。按照此方案使用时，Didemnin B对既往接受过治疗的上皮性卵巢癌患者无效。
